The 2019 medical conference brings important information on managing arthritis among Hispanic patient populations.
Already approved for rheumatoid arthritis, upadacitinib may help other inflammatory conditions as well.
There was an increased risk of many different kinds of side effects, but most were mild.
The 2019 medical conference brings important information on osteoarthritis drug therapies, better understanding of diseases causes and symptom management, and more ways to help patients feel better.
By Joseph Coe
The 2019 medical conference brings important information on PsA drug therapies, better understanding of diseases causes and symptom management, and more ways to help patients feel better.
The 2019 medical conference brings important information on gout drug therapies, better understanding of diseases causes and symptom management, and more ways to help patients feel better.
The 2019 medical conference brings important information on axSpA drug therapies, better understanding of diseases causes and symptom management, and more ways to help patients feel better.
The 2019 medical conference brings important information on RA drug therapies, better understanding of diseases causes and symptom management, and more ways to help patients feel better.
The 2019 medical conference brings important information on new drug therapies, better understanding of diseases causes and symptom management, and more ways to help patients feel better.
Anifrolumab will seek FDA approval.
This may be a good option for patients who shouldn’t use NSAIDs or colchicine to treat gout flares.
"Giant cell arteritis requires ongoing management, but it does not necessarily require continuous treatment.”
Researchers are very interested in seeing which factors might be used to predict — and help prevent — rheumatoid arthritis in at-risk people.
This is eye-opening and important for lupus patients to know: African Americans with lupus were 18 times more likely than Caucasian patients to suffer a cardiovascular event during a 10-year period.
By Susan Ince
With advancements in rheumatoid arthritis medication, those with osteoarthritis may now have a higher disease burden overall.
By Susan Ince
Screening is important because silent hepatitis B and C infections can spring to life when you start biologics or new synthetic DMARDs.
A new study adds support to the theory that psychological stress might increase the risk of fibromyalgia and make symptoms worse.
This is important news since type 2 diabetes and gout have many risk factors in common to begin with.
As the temperature increased, so did the risk of rash, joint inflammation, kidney problems, and other lupus symptoms.
By Susan Ince
Researchers hope that identifying the link between respiratory issues and RA will result in better ways to prevent or screen for rheumatoid arthritis in people with lung disease.
By Susan Ince
New data compares what happens when the dosage of DMARDs such as methotrexate is tapered or kept steady.
Already approved for psoriasis, the IL-23 inhibitor is looking good for patients with psoriatic arthritis.
Knowing there could be a lag between objective measures of improvement and patient-reported outcomes could help prevent over-treatment.
By Susan Ince
Although biologics cross the placenta, research shows they lead to few infections in babies after they’re born.
By Susan Ince
Surprisingly, stronger opioids were the worst at relieving pain in a new multi-study analysis.
By Joseph Coe
New data from the Centers for Disease Control and Prevention (CDC) suggests that arthritis might be a leading cause of chronic pain in the U.S.
"This may have implications for management decisions beyond treating to disease activity targets alone."
Female patients were much more likely to have a dual diagnosis.
And a few factors seemed to be responsible, including being obese and also having fibromyalgia.
‘Art enables me to face my body and my life with courage.’
In new ArthritisPower research, whether or not medical marijuana is legal seems to affect whether patients use it, and importantly, whether they talk to their doctor about it.
But the majority of MTX users felt that the medication protects them from getting worse, according to a new study.
In new ArthritisPower research, patients said they wanted to track symptoms such as fatigue and aspects of mental health, such as depression and anxiety.
By 
By 
By 
By 
